Biopharmaceutical company focused on metabolic and liver diseases.
Genfit S.A., a biopharmaceutical company, focuses on the discovery and development of drug candidates and diagnostic solutions targeting metabolic and liver-related diseases. The company's lead product, Elafibranor, is currently in Phase 3 clinical trials for treating primary biliary cholangitis. Genfit is also advancing its NIS4 technology for diagnosing nonalcoholic steatohepatitis (NASH) and fibrosis, positioning itself at the forefront of liver disease diagnostics.
Additionally, Genfit is developing GNS561, an investigational treatment for cholangiocarcinoma (CCA) that is in Phase 1b/2 trials, and Nitazoxanide, which is in Phase 1 trials for treating acute-on-chronic liver failure. The company's innovative approach to liver disease treatment and diagnostics highlights its commitment to addressing significant unmet medical needs in this therapeutic area.
Headquartered in Loos, France, and incorporated in 1999, Genfit has established strategic partnerships to enhance its product pipeline. These include a licensing agreement with Labcorp to commercialize NASHnext, a blood-based molecular diagnostic test, and a collaboration with Genoscience Pharma to develop and commercialize GNS561 for CCA. Through these alliances and its robust research efforts, Genfit continues to advance its mission of improving patient outcomes in liver disease.